Loxo Oncology, Inc. (NASDAQ:LOXO) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued on Friday.

A number of other brokerages have also weighed in on LOXO. Zacks Investment Research upgraded shares of Loxo Oncology from a “sell” rating to a “hold” rating in a report on Thursday, June 8th. BTIG Research restated a “buy” rating and issued a $75.00 price objective on shares of Loxo Oncology in a report on Thursday. Stifel Nicolaus restated a “buy” rating and issued a $71.00 price objective on shares of Loxo Oncology in a report on Thursday. Morgan Stanley restated an “overweight” rating and issued a $91.00 price objective on shares of Loxo Oncology in a report on Monday, June 19th. Finally, Cowen and Company restated an “outperform” rating on shares of Loxo Oncology in a report on Monday, June 5th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $70.83.

Shares of Loxo Oncology (NASDAQ LOXO) traded down 0.23% during trading on Friday, reaching $72.75. 149,569 shares of the company traded hands. The firm’s 50-day moving average is $75.53 and its 200-day moving average is $53.18. The stock’s market capitalization is $1.90 billion. Loxo Oncology has a 12-month low of $17.14 and a 12-month high of $83.12.

Loxo Oncology (NASDAQ:LOXO) last announced its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.76) by $0.20. On average, equities analysts predict that Loxo Oncology will post ($4.22) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Loxo Oncology, Inc. (NASDAQ:LOXO) Stock Rating Lowered by BidaskClub” was published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another publication, it was illegally copied and republished in violation of U.S. and international copyright laws. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/08/07/loxo-oncology-inc-nasdaqloxo-stock-rating-lowered-by-bidaskclub.html.

In related news, Director Keith T. Flaherty sold 7,250 shares of the company’s stock in a transaction on Monday, May 22nd. The shares were sold at an average price of $45.09, for a total transaction of $326,902.50. Following the completion of the sale, the director now directly owns 27,141 shares in the company, valued at approximately $1,223,787.69. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 27.80% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. State Street Corp increased its position in shares of Loxo Oncology by 2.1% in the fourth quarter. State Street Corp now owns 214,321 shares of the biopharmaceutical company’s stock worth $6,882,000 after buying an additional 4,360 shares during the last quarter. Teachers Advisors LLC increased its position in shares of Loxo Oncology by 4.3% in the fourth quarter. Teachers Advisors LLC now owns 22,139 shares of the biopharmaceutical company’s stock worth $711,000 after buying an additional 905 shares during the last quarter. Candriam Luxembourg S.C.A. increased its position in shares of Loxo Oncology by 28.8% in the first quarter. Candriam Luxembourg S.C.A. now owns 103,000 shares of the biopharmaceutical company’s stock worth $4,334,000 after buying an additional 23,000 shares during the last quarter. Nationwide Fund Advisors increased its position in shares of Loxo Oncology by 31.9% in the first quarter. Nationwide Fund Advisors now owns 27,434 shares of the biopharmaceutical company’s stock worth $1,154,000 after buying an additional 6,632 shares during the last quarter. Finally, Wells Fargo & Company MN increased its position in shares of Loxo Oncology by 33.3% in the first quarter. Wells Fargo & Company MN now owns 15,503 shares of the biopharmaceutical company’s stock worth $653,000 after buying an additional 3,875 shares during the last quarter.

About Loxo Oncology

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Analyst Recommendations for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.